Senator Hinojosa Supports Legislation to Combat Dementia in Texas

Translate to Spanish or other 102 languages!

The Texas Senate took a significant step forward in the fight against dementia by passing Senate Bill (SB) 5 and Senate Joint Resolution (SJR) 3, both authored by Senator Joan Huffman. Senator Juan “Chuy” Hinojosa, who co-authored these bills, expressed his strong support for the potential establishment of the Dementia Prevention and Research Institute of Texas (DPRIT). Image for illustration purposes
- Advertisement -

AUSTIN, Texas – The Texas Senate took a significant step forward in the fight against dementia by passing Senate Bill (SB) 5 and Senate Joint Resolution (SJR) 3, both authored by Senator Joan Huffman. Senator Juan “Chuy” Hinojosa, who co-authored these bills, expressed his strong support for the potential establishment of the Dementia Prevention and Research Institute of Texas (DPRIT).

Senator Hinojosa stated, “There are few bills that we will pass this session that will have as significant of an impact for future generations as these dementia bills. This program is modeled after the Cancer Prevention & Research Institute of Texas (CPRIT), and we have seen how that research has transformed cancer treatment for patients. I appreciate Lieutenant Governor Dan Patrick for making this issue a priority and Senator Huffman for her leadership and commitment.”

SB 5 would establish DPRIT to focus on accelerating research into dementia and related disorders, enhancing innovation, and ultimately improving the health of Texans. With the alarming rise of dementia diagnoses—especially among Hispanic populations—this initiative is crucial. “Dementia is not just a medical issue; it’s a personal one that affects families and communities. We must prioritize research and resources to ensure that all Texans have access to the best possible care and support,” Senator Hinojosa added.

- Advertisement -

SJR 3 proposes a constitutional amendment that would transfer $3 billion in state funds to the Dementia Prevention & Research Fund, ensuring funding for the next ten years, with a limit of $300 million in appropriations per fiscal year. This fund will support research into the causes, prevention, treatment, and rehabilitation of dementia, creating high-quality jobs and attracting top researchers to Texas.

Currently, approximately 400,000 Texans aged 65 and older are living with Alzheimer’s disease, and the costs associated with care are substantial, with Texas Medicaid expenses estimated to be nearly $4 billion in 2024. Additionally, research indicates that Hispanics will continue to experience a steep increase in dementia diagnoses among all racial and ethnic groups, yet they are underrepresented in clinical trials.

Senator Hinojosa emphasized, “DPRIT is designed to make Texas a leader in combating dementia. In the RGV we have the UTRGV Alzheimer’s Disease Resource Center for Minority Aging Research. This center will benefit from DPRIT and the significant investment of $3 billion. These funds will speed up research to help us learn more about this terrible disease, how we can prevent it, and eventually cure it.”

The establishment of DPRIT marks a historic commitment to improving the quality of life for those impacted by dementia and ensuring that Texas remains at the forefront of medical research and innovation. The bills are now in the Texas House for consideration.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Beat the Summer Heat: Essential Hydration Tips

Summer heat has a way of sneaking up on you, making it easy to become dehydrated before you even realize you're thirsty.

STHS’ Transform Your Life Event Inspires Healthier Living Across the RGV

Whether you're making healthier food choices, becoming more active or focusing on your mental well-being, every positive change can help you live a longer, healthier and more fulfilling life.

STHS Dedicating Latest “South Texas Healthy Living” Episode to Arthritis Education, July 26th

More than 58 million U.S. adults are living with doctor-diagnosed arthritis, according to the Centers for Disease Control and Prevention (CDC), making it the nation’s leading cause of disability.

No More Needles: FDA Approves First Daily Pill to Replace Injectable Cholesterol Drugs

The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Image source: Merck.com.
- Advertisement -